The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response assessment of novoTTF-100A versus best physician’s choice chemotherapy in recurrent glioblastoma.
Eric Wong
Consultant or Advisory Role - Novocure (U)
Research Funding - Novocure
Edwin Lok
No relevant relationships to disclose
Kenneth D. Swanson
Research Funding - Novocure
Shiva Gautam
No relevant relationships to disclose
Herbert H. Engelhard
Consultant or Advisory Role - Novocure (U)
Frank S. Lieberman
No relevant relationships to disclose
Sophie Taillibert
No relevant relationships to disclose
Zvi Ram
Consultant or Advisory Role - Novocure (U)
Stock Ownership - Novocure
John L. Villano
Consultant or Advisory Role - Novocure (U)